Kytopen is pioneering a novel and non-viral process to engineer human cells for therapeutic applications in immuno-oncology and genetic disorders.
Location: United States, Massachusetts, Cambridge
Total raised: $33.6M
Investors 3
| Date | Name | Website |
| 29.01.2023 | Bantam Gro... | bantamgrou... |
| 24.08.2022 | MassVentur... | mass-ventu... |
| - | TBD Angels | tbdangels.... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.09.2021 | Series A | $30M | - |
| 29.05.2019 | Seed | $3.6M | - |
Mentions in press and media 17
| Date | Title | Description |
| 08.04.2024 | Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer | CAMBRIDGE, Mass. and DENVER, April 8, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, today announced the appointment of Kevin Gutshall as Chief Co... |
| 26.03.2024 | Kytopen Announces Launch of Technology Access Program Supported by an Expanded Applications Team | CAMBRIDGE, Mass. and DENVER, March 26, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, announces the launch of the Flowfect® Technology Access Prog... |
| 13.01.2023 | Slone Partners Places Paul Wotton, Ph.D. as Chair of Board of Directors at Kytopen | “Paul Wotton is an extremely accomplished and talented leader and visionary in biotech, advanced cell technology, and biopharmaceutical research, discovery, and marketing,” said Slone Partners CEO Leslie Loveless. SOUTH RIDING, Va. (PRWEB) ... |
| 28.09.2021 | Amplitude CEO’s ode to scrutiny ahead of going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content To retain talent, employers can't skip on fertility benefits From Maven Clinic To th... |
| 28.09.2021 | MIT cell-engineering spinout nets $30M for mass manufacturing platform | One of the tricks of getting cell therapies to work is getting the payload you want into the cell itself—be it RNA, DNA or CRISPR proteins, that genetic information is necessary to bend the cell toward becoming a real therapeutic. So far, t... |
| 28.09.2021 | Amplitude CEO’s ode to scrutiny ahead of going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Why the Electricity 4.0 moment is here From Schneider Electric To the chagrin of man... |
| 28.09.2021 | MIT cell-engineering spinout nets $30M for mass manufacturing platform | One of the tricks of getting cell therapies to work is getting the payload you want into the cell itself—be it RNA, DNA or CRISPR proteins, that genetic information is necessary to bend the cell toward becoming a real therapeutic. Originall... |
| 28.09.2021 | Kytopen Raises $30M in Series A Funding | Kytopen Corp., a Cambridge, Mass.-based biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, raised $30m in Series A funding. The round was led by Northpond Ventures, with participation from cu... |
| 28.09.2021 | Kytopen Raises $30M in Series A Funding, Led by Northpond Ventures, to Transform Non-Viral Delivery via the Flowfect Platform | Kytopen Corp., a biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, today announced it has raised $30 million in an oversubscribed Series A funding. The new capital will be used to commercial... |
| 23.03.2021 | Biocentriq™ and Kytopen® Partner to Demonstrate Impact of Transformative Technology On Cell Therapy Manufacturing | “Our goal is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to help patients; our partnership with BioCentriq accelerates that goal.” NEWARK, N.J. (PRWEB) March 23, 2021 BioCentriq™, the New Je... |
Show more